San Antonio-based Seno Medical Instruments, Inc. recently announced that the company has added Thomas Stavros, MD, FACR, FSRU, FRANZCR, as their new Medical Director, who will bring his expertise in breast radiology to the further development of Seno’s technological offerings.
Dr. Stavros brings a great deal of experience and expertise to Seno’s executive staff, which remains focused on the continued development and commercialization of their innovative Imagio breast imaging system.
He serves as an active, practicing women’s imaging radiologist at Sutter Medical Group in Sacramento, California, and has over 30 years of practical breast imaging experience. Over the course of his work history Dr. Stavros has been involved in the rapid progression of mammography and mammography technology, particularly in the development of high-frequency hand-held breast ultrasounds, which he has been involved with since 1981.
In addition, he serves as a reviewer for several highly-regarded medical journals, has authored or co-authored numerous articles within his discipline, and also authored the Breast Ultrasound textbook, which serves as the definitive text on this subject in the United States. Dr. Stavros also continues to lecture about ultrasound technology and methodology throughout the world, and has presented more than 1,800 invited lectures and abstracts worldwide.
He has also been recognized and awarded by some of the most prestigious universities and research institutions involved in ultrasound and breast health as well, earning a fellowship from the American College of Radiology and the Society of Radiologists in Ultrasound, as well as an honorary fellowship from the Royal Australian and New Zealand College of Radiology, where he was the Traveling Baker Professor in 1999. His educational background began at the University of Colorado School of Medicine in Denver where he received his medical degree, and also received a bachelor’s degree from St. Olaf College in Minnesota.
In addition to his hands-on experience in the healthcare field and numerous academic awards, Dr. Stavros has experience working with the biotech private sector as well, having served as a clinical advisor for several ultrasound, breast imaging, and minimally invasive biopsy device companies such as General Electric, Philips, and Ethicon Endo-Surgery.
On his new appointment to Seno’s executive staff, Dr. Stavros commented, “I am excited to join the Seno management team and help the company in its quest to develop and commercialize opto-acoustic imaging, which I believe could become a new standard in cancer diagnosis,” adding, “I’ve spent my career working to develop safe and effective breast imaging solutions, and I believe opto-acoustic technology has the potential to significantly improve the breast cancer diagnostic and treatment path. The sad reality is that 80% of biopsies ultimately return negative results due to limitations of current imaging modalities. The Imagio system produces some of the most exciting images depicting angiogenesis and oxygen levels within and around suspicious masses that I’ve seen in my career and could enable us to more precisely diagnose or rule out breast cancer.”
Dr. Stavros’ well-rounded skill set and indisputable position as a leading innovator in breast imaging makes him a perfect candidate for helping Seno continue to develop the Imagio breast imaging system, which uses a combination of traditional breast ultrasound co-registered with opto-acoustic technology, and provides physicians real time anatomical images of the breast with a functional “blood map” of a potentially suspicious mass.
Janet Campbell, CEO of Seno Medical Instruments, sees great promise in the appointment of Stavros as Medical Director the company, commenting: “Dr. Stavros’ unprecedented experience in breast imaging using ultrasound makes him an ideal Medical Director for our company. We are proud to have him join our team,” adding that, “Tom is one of the leading minds in the field driving our clinical development path and helping us in our goal to improve the diagnosis of breast cancer for women around the globe. He brings invaluable clinical experience that will help facilitate development of Imagio and help us bring this important technology to commercialization.”
Photo from http://www.sonocine.com